These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37655106)

  • 1. An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer.
    Qi Y; Gu L; Shen J; Yao Y; Zhao Y; Lu S; Chen Z
    Front Oncol; 2023; 13():1194100. PubMed ID: 37655106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis.
    Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S
    Front Immunol; 2022; 13():938269. PubMed ID: 36059450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
    Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
    Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.
    Fang M; Hang Q; Jiang H; Cai L; Hu J; Ying H; Gu Q; Yu X; Liu J; Lai X
    Front Oncol; 2022; 12():1055610. PubMed ID: 36713546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials.
    Yu A; Fu F; Li X; Wu M; Yu M; Zhang W
    Front Oncol; 2024; 14():1351359. PubMed ID: 38454928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
    Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
    Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
    Lei J; Zhao J; Gong L; Ni Y; Zhou Y; Tian F; Liu H; Gu Z; Huang L; Lu Q; Wang X; Sun J; Yang E; Wang T; Zhong D; Wang J; Zhao Z; Liu Z; Wang C; Wang X; Lei G; Yan X; Jiang T
    JAMA Oncol; 2023 Oct; 9(10):1348-1355. PubMed ID: 37535377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    Forde PM; Spicer J; Lu S; Provencio M; Mitsudomi T; Awad MM; Felip E; Broderick SR; Brahmer JR; Swanson SJ; Kerr K; Wang C; Ciuleanu TE; Saylors GB; Tanaka F; Ito H; Chen KN; Liberman M; Vokes EE; Taube JM; Dorange C; Cai J; Fiore J; Jarkowski A; Balli D; Sausen M; Pandya D; Calvet CY; Girard N;
    N Engl J Med; 2022 May; 386(21):1973-1985. PubMed ID: 35403841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.
    Wu J; Hou L; E H; Zhao Y; Yu X; Xu L; Ning Y; Deng J; Sun K; Zhang J; Wu C; Zhu Y; Zhao D; She Y; Su C; Chen C
    Lung Cancer; 2022 Mar; 165():115-123. PubMed ID: 35123154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer.
    Tao Y; Li X; Liu B; Wang J; Lv C; Li S; Wang Y; Chen J; Yan S; Wu N
    Front Oncol; 2023; 13():1135140. PubMed ID: 37256186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
    Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
    Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.
    Wang C; Chen KN; Chen Q; Wu L; Wang Q; Li X; Ying K; Wang W; Zhao J; Liu L; Fu J; Zhang C; Liu J; Hu Y; Ntambwe I; Cai J; Bushong J; Tran P; Lu S
    ESMO Open; 2023 Dec; 8(6):102040. PubMed ID: 37922691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
    Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
    J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
    Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
    BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study.
    Duan H; Wang T; Luo Z; Tong L; Dong X; Zhang Y; Afzal MZ; Correale P; Liu H; Jiang T; Yan X
    Transl Lung Cancer Res; 2021 Feb; 10(2):1020-1028. PubMed ID: 33718040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.